利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

42 条记录 (耗时 0.039 秒)

    ID SYMBOL UNIQUE TO STRUCTURAL FORMULA OF COMPOUND
    4.
    发明申请
    ID SYMBOL UNIQUE TO STRUCTURAL FORMULA OF COMPOUND 审中-公开
    ID符号结构化合物的结构

    公开(公告)号：US20070027900A1

    公开(公告)日：2007-02-01

    申请号：US11381497

    申请日：2006-05-03

    申请人： Tetsuro TOYODA ,  Akiko ITAI

    发明人： Tetsuro TOYODA ,  Akiko ITAI

    IPC分类号： G06F7/00

    CPC分类号： G16C20/80 ,  G16C20/40 ,  G16C20/90

    摘要： A method for generating a character string of fixed or variable length which is substantially unique with respect to a chemical structural formula, on the basis of the kind of each atom constituting the compound and the bonding relation of the atoms and/or the kind of isomers, and employing the character string as an ID symbol of the said compound, and a method for converting the above-mentioned character string to data or a character string of smaller data size by using a character string converting function and employing it as the ID symbol of the said compound.

    摘要翻译： 基于构成化合物的每个原子的种类和原子和/或异构体的种类的键合关系，生成相对于化学结构式基本上独特的固定或可变长度的字符串的方法 并且使用字符串作为所述化合物的ID符号，以及通过使用字符串转换功能并将其用作ID符号将上述字符串转换为数据或较小数据大小的字符串的方法 的所述化合物。

    O-SUBSTITUTED HYDROXYARYL DERIVATIVES
    5.
    发明申请
    O-SUBSTITUTED HYDROXYARYL DERIVATIVES 审中-公开
    O-取代的羟基衍生物

    公开(公告)号：US20100113770A1

    公开(公告)日：2010-05-06

    申请号：US12579168

    申请日：2009-10-14

    申请人： Susumu MUTO ,  Akiko ITAI

    发明人： Susumu MUTO ,  Akiko ITAI

    IPC分类号： C07C229/40 ,  C07D213/80 ,  C07D211/06 ,  C07C271/10 ,  C07F9/08 ,  C07D295/14 ,  C07D267/00 ,  C07D265/14

    CPC分类号： C07D209/48 ,  C07D211/62 ,  C07D213/803 ,  C07D265/22 ,  C07D265/26 ,  C07D269/00 ,  C07D273/00 ,  C07D277/46 ,  C07D295/185 ,  C07D295/205 ,  C07D309/10 ,  C07D317/60 ,  C07K5/06052 ,  C07K5/06078 ,  C07K5/06086 ,  C07K5/06113 ,  C07K5/06191

    摘要： A medicament having inhibitory activity against NF-κB activation which comprises as an active ingredient a substance selected from the group consisting of a compound represented by the following general formula (I) and a pharmacologically acceptable salt thereof, and a hydrate thereof and a solvate thereof: wherein X represents a connecting group whose number of atoms in a main chain is 2 to 5 (said connecting group may be substituted), “A” represents an acyl group which may be substituted, (provided that unsubstituted acetyl group and unsubstituted acryloyl group are excluded,) or a C1 to C6 alkyl group which may be substituted, or A may bind to connecting group X to form a cyclic structure which may be substituted, “E” represents an aryl group which may be substituted or a heteroaryl group which may be substituted, ring Z represents an arene which may have one or more substituents in addition to the group represented by formula —O-A wherein A has the same meaning as that defined above and the group represented by formula —X-E wherein each of X and E has the same meaning as that defined above, or a heteroarene which may have one or more substituents in addition to the group represented by formula —O-A wherein A has the same meaning as that defined above and the group represented by formula —X-E wherein each of X and E has the same meaning as that defined above.

    摘要翻译： 一种具有对NF-κB活化的抑制活性的药物，其包含作为活性成分的选自下述通式（I）表示的化合物及其药理学可接受的盐及其水合物和 溶剂合物：其中X表示主链中的原子数为2〜5的连接基团（所述连接基团可以被取代），“A”表示可以被取代的酰基（条件是未取代的乙酰基和未取代的 丙烯酰基除外）或可被取代的C1-C6烷基，或A可以与连接基团X结合以形成可被取代的环状结构，“E”表示可被取代的芳基或杂芳基 可以被取代的基团，Z表示除了由式-OA表示的基团之外可以具有一个或多个取代基的芳烃，其中A具有与tha相同的含义 t和由式-XE表示的基团，其中X和E各自具有与上述相同的含义，或除了由式-OA表示的基团之外还可以具有一个或多个取代基的杂芳烃，其中A具有 与上述定义相同的含义和由式-XE表示的基团，其中X和E各自具有与上述相同的含义。

    N-(3,4-disubstituted phenyl) salicylamide derivatives
    6.
    发明授权
    N-(3,4-disubstituted phenyl) salicylamide derivatives 失效
    N-（3,4-二取代苯基）水杨酰胺衍生物

    公开(公告)号：US07671058B2

    公开(公告)日：2010-03-02

    申请号：US11765011

    申请日：2007-06-19

    申请人： Ryukou Tokuyama ,  Toshifumi Wakamatsu ,  Tatsurou Ichige ,  Susumu Muto ,  Akiko Itai

    发明人： Ryukou Tokuyama ,  Toshifumi Wakamatsu ,  Tatsurou Ichige ,  Susumu Muto ,  Akiko Itai

    IPC分类号： A01N43/42 ,  A61K31/44 ,  C07D241/04 ,  C07D295/00

    CPC分类号： C07D207/12 ,  C07C235/64 ,  C07C2601/14 ,  C07D207/06 ,  C07D207/14 ,  C07D211/22 ,  C07D211/26 ,  C07D211/30 ,  C07D211/42 ,  C07D211/46 ,  C07D211/58 ,  C07D211/60 ,  C07D211/74 ,  C07D213/40 ,  C07D241/04 ,  C07D241/08 ,  C07D243/08 ,  C07D295/12 ,  C07D295/135 ,  C07D295/185 ,  C07D295/205 ,  C07D491/113

    摘要： A compound represented by the following formula (I) or a salt thereof: wherein R1, R2, R3 and R4 represent hydrogen atom, a halogen atom, cyano group, nitro group, a C1-4 alkyl group, a halogenated C1-4 alkyl group or a C1-4 alkoxy group, R5 represents a halogen atom, cyano group, a C1-4 alkyl group, a halogenated C1-4 alkyl group or a C1-4 alkoxy group, R6 represents a C5-7 cycloalkyl group, a substituted C5-7 cycloalkyl group, a 5 to 7-membered completely saturated heterocyclic group or a substituted 5 to 7-membered completely saturated heterocyclic group, X represents a single bond, oxygen atom, sulfur atom, NR7, —O—CH2— or —N(R8)—CH2—, R7 represents hydrogen atom or a C1-4 alkyl group, or R7 may combine with a substituent of R6 to represent a single bond, methylene group or ethylene group, R8 represents hydrogen atom, a C1-4 alkyl group or a C7-12 aralkyl group, which is useful as an active ingredient of a medicament for prophylactic and/or therapeutic treatment of diseases caused by an activation of STAT6 and/or NF-κB.

    摘要翻译： 由下式（I）表示的化合物或其盐：其中R1，R2，R3和R4表示氢原子，卤素原子，氰基，硝基，C1-4烷基，卤代C1-4烷基 基或C 1-4烷氧基，R 5表示卤素原子，氰基，C 1-4烷基，卤代C 1-4烷基或C 1-4烷氧基，R 6表示C 5-7环烷​​基， 取代的C 5-7环烷​​基，5至7元完全饱和的杂环基或取代的5至7元完全饱和的杂环基，X表示单键，氧原子，硫原子，NR 7，-O-CH 2 - 或 -N（R 8）-CH 2 - ，R 7表示氢原子或C 1-4烷基，或者可以与R 6的取代基结合，表示单键，亚甲基或亚乙基，R 8表示氢原子， 4烷基或C7-12芳烷基，其可用作用于预防和/或治疗疾病的药物的活性成分 由STAT6和/或NF-和kgr的活化引起的;

    O-substituted hydroxyaryl derivatives
    7.
    发明授权
    O-substituted hydroxyaryl derivatives 有权
    O-取代的羟基芳基衍生物

    公开(公告)号：US07626042B2

    公开(公告)日：2009-12-01

    申请号：US10515622

    申请日：2003-06-05

    申请人： Susumu Muto ,  Akiko Itai

    发明人： Susumu Muto ,  Akiko Itai

    IPC分类号： A61K31/40 ,  A61K31/445 ,  A61K31/495 ,  A61K31/5375 ,  C07D207/16 ,  C07D241/04 ,  C07D265/30

    CPC分类号： C07D209/48 ,  C07D211/62 ,  C07D213/803 ,  C07D265/22 ,  C07D265/26 ,  C07D269/00 ,  C07D273/00 ,  C07D277/46 ,  C07D295/185 ,  C07D295/205 ,  C07D309/10 ,  C07D317/60 ,  C07K5/06052 ,  C07K5/06078 ,  C07K5/06086 ,  C07K5/06113 ,  C07K5/06191

    摘要： A medicament having inhibitory activity against NF-κB activation which comprises as an active ingredient a substance selected from the group consisting of a compound represented by the following general formula (I) and a pharmacologically acceptable salt thereof, and a hydrate thereof and a solvate thereof: wherein X represents a connecting group whose number of atoms in a main chain is 2 to 5 (said connecting group may be substituted), “A” represents an acyl group which may be substituted, (provided that unsubstituted acetyl group and unsubstituted acryloyl group are excluded,) or a C1 to C6 alkyl group which may be substituted, or A may bind to connecting group X to form a cyclic structure which may be substituted, “E” represents an aryl group which may be substituted or a heteroaryl group which may be substituted, ring Z represents an arene which may have one or more substituents in addition to the group represented by formula —O-A wherein A has the same meaning as that defined above and the group represented by formula —X-E wherein each of X and E has the same meaning as that defined above, or a heteroarene which may have one or more substituents in addition to the group represented by formula —O-A wherein A has the same meaning as that defined above and the group represented by formula —X-E wherein each of X and E has the same meaning as that defined above.

    摘要翻译： 一种具有抑制NF-κB活化活性的药物，其特征在于，含有选自下述通式（I）表示的化合物及其药理学可接受的盐及其水合物及其溶剂合物作为活性成分的物质 ：其中X表示主链中的原子数为2〜5的连接基（所述连接基可以被取代），“A”表示可以被取代的酰基（条件是未取代的乙酰基和未取代的丙烯酰基 或者可以被取代的C1〜C6烷基，或者A可以与连接基团X结合形成可以被取代的环状结构，“E”表示可被取代的芳基或杂芳基， 可以被取代，环Z表示除了由式-OA表示的基团之外可以具有一个或多个取代基的芳烃，其中A具有与所定义的相同的含义 以及由式-XE表示的基团，其中X和E各自具有与上述相同的含义，或除了由式-OA表示的基团之外还可以具有一个或多个取代基的杂芳烃，其中A具有相同的含义 如上所定义的基团和由式-XE表示的基团，其中X和E各自具有与上述相同的含义。

    Carboxilic acid derivatives
    8.
    发明申请
    Carboxilic acid derivatives 失效
    羧酸衍生物

    公开(公告)号：US20080275116A1

    公开(公告)日：2008-11-06

    申请号：US11870718

    申请日：2007-10-11

    申请人： Youichi YAMAGUCHI ,  Takeshi YANASE ,  Susumu MUTO ,  Akiko ITAI

    发明人： Youichi YAMAGUCHI ,  Takeshi YANASE ,  Susumu MUTO ,  Akiko ITAI

    IPC分类号： A61K31/235 ,  A61K31/195 ,  C07C63/04 ,  C07C69/78 ,  A61K31/192 ,  A61P7/04 ,  A61P7/02

    CPC分类号： C07C51/00 ,  C07C59/64 ,  C07C65/24 ,  C07C65/28 ,  C07C205/06 ,  C07C205/34 ,  C07C217/86 ,  C07C235/80 ,  C07C255/37

    摘要： A compound represented by the following general formula (I) or a salt thereof, or a hydrate thereof or a solvate thereof having an inhibitory action against plasminogen activator inhibitor-1 (PAI-1): wherein R1 represents a C6-10 aryl group; or a substituted C6-10 aryl group, R2 represents a C6-10 aryl group; or a C6-10 aryl group substituted with a group or groups selected from the group consisting of a halogen atom, nitro group, a C1-6 alkyl group, a halogenated C1-6 alkyl group, a C1-6 alkoxy group, a halogenated C1-6 alkoxy group, a phenyl group and carboxy group, X represents —CH2—, —CH2CH2—, —CH═CH— or —N(R3)—C(═O)—, Y represents carboxy group or a bioisostere of carboxy group, R3 represents hydrogen atom, a C1-4 alkyl group or a C7-12 aralkyl group, m represents 0 or 1.

    摘要翻译： 具有对纤溶酶原激活物抑制剂-1（PAI-1）具有抑制作用的由以下通式（I）表示的化合物或其盐，或其水合物或其溶剂化物：其中R 1， 表示C 6-10芳基; 或取代的C 6-10芳基，R 2表示C 6〜6-10芳基; 或被选自卤素原子，硝基，C 1-6烷基的基团或基团取代的C 6-10芳基， 卤代C 1-6烷基，C 1-6烷氧基，卤代C 1-6烷氧基，苯基和 羧基，X表示-CH 2 - ， - CH 2 CH 2 - ， - CH-CH-或-N（R' C（-O） - ，Y表示羧基或羧基的生物电子等排物，R 3表示氢原子，C 1-4烷基 >烷基或C 7-12-12芳烷基，m表示0或1。

    Antiallergic agents
    9.
    发明申请
    Antiallergic agents 审中-公开
    抗过敏剂

    公开(公告)号：US20070185059A1

    公开(公告)日：2007-08-09

    申请号：US11783325

    申请日：2007-04-09

    申请人： Susumu Muto ,  Akiko Itai

    发明人： Susumu Muto ,  Akiko Itai

    IPC分类号： A61K31/695 ,  A61K31/5375 ,  A61K31/40 ,  A61K31/445 ,  A61K31/426 ,  A61K31/277 ,  A61K31/165

    CPC分类号： C07D295/192 ,  A61K31/055 ,  A61K31/137 ,  A61K31/15 ,  A61K31/165 ,  A61K31/167 ,  A61K31/18 ,  A61K31/357 ,  A61K31/381 ,  A61K31/40 ,  A61K31/403 ,  A61K31/4035 ,  A61K31/404 ,  A61K31/421 ,  A61K31/422 ,  A61K31/427 ,  A61K31/445 ,  A61K31/4453 ,  A61K31/455 ,  A61K31/47 ,  A61K31/498 ,  A61K31/5375 ,  A61K31/606 ,  A61K31/609 ,  A61K31/616 ,  A61K31/63 ,  C07C235/64

    摘要： A medicament for the preventive and/or therapeutic treatment of allergic diseases and/or endometriosis and/or hysteromyoma which comprises as an active ingredient a substance selected from the group consisting of a compound represented by the following general formula (I) and a pharmacologically acceptable salt thereof, and a hydrate thereof and a solvate thereof: wherein X represents a connecting group whose number of atoms in the main chain is 2 to (said connecting group may be substituted), A represents hydrogen atom or acetyl group, E represents an aryl group which may be substituted or a hetero aryl group which may be substituted, ring Z represents an arene which may have one or more substitutents in addition to the group represented by formula —O-A wherein A has the same meaning as that defined above and the group represented by formula —X-E wherein each of X and E has the same meaning as that defined above, or a heteroarene which may have one or more substitutents in addition to the group represented by formula —O-A wherein A has the same meaning as that defined above and the group represented by formula —X-E wherein each of X and E has the same meaning as that defined above.

    摘要翻译： 一种用于预防和/或治疗过敏性疾病和/或子宫内膜异位症和/或子宫肌瘤的药物，其包含作为活性成分的选自以下通式（I）表示的化合物和药理学上可接受的物质 盐及其水合物及其溶剂合物：其中X表示主链中的原子数为2的连接基团（所述连接基团可以被取代），A表示氢原子或乙酰基，E表示芳基 可以被取代的基团或可以被取代的杂芳基，环Z表示除了由式-OA表示的基团之外还可以具有一个或多个取代基的芳烃，其中A具有与上述相同的含义，并且基团 由式-XE表示，其中X和E各自具有与上述相同的含义，或者除了具有一个或多个取代基的杂芳烃 由式-O-A表示的基团，其中A具有与上述定义相同的含义和由式-X-E表示的基团，其中X和E各自具有与上述相同的含义。